GlycoMimetics, Inc (Nasdaq:GLYC) stock moved up a bit on Wednesday after the company issued news today.
As of 10:43, GLYC stock gained 1.28% to $2.30. So far more than 295K shares have traded hands, compared to its average volume of 898K shares. The stock opened at $2.37 and moved within a narrow range of $2.2700 – 2.3765.
INND Issues News
GlycoMimetics Announces Investigator-Sponsored Phase 2 Clinical Trial Evaluating Uproleselan for Prevention of Gastro-Intestinal Toxicity in Autologous Hematopoietic Cell Transplantation
- announced today that clinicians at Washington University School of Medicine in St. Louis have dosed the first patient in an investigator-sponsored trial (IST) evaluating uproleselan as a prophylactic agent to reduce gastrointestinal (GI) toxicities associated with high-dose melphalan in autologous hematopoietic cell transplantation (auto-HCT) for multiple myeloma (MM).
- Dr. Keith Stockerl-Goldstein, M.D., Professor of Medicine, Division of Oncology, Section of Bone Marrow Transplantation, Washington University School of Medicine, is the clinical trial’s principal investigator.
“GI side effects are the dose-limiting toxicities of high-dose melphalan in autologous hematopoietic stem-cell transplantation. Preclinical data have demonstrated a protective effect of uproleselan against mucosal damage and, in the GlycoMimetics Phase 2 trial reported at the American Society of Hematology (ASH) meeting in 2018, uproleselan demonstrated the potential to mitigate severe mucositis in relapsed and refractory acute myeloid leukemia (AML) patients undergoing intensive chemotherapy,” said Eric J. Feldman, M.D., GlycoMimetics’ Chief Medical Officer.
|+/- EMA(20)||2.43 (-5.35%)|
|+/- SMA(50)||2.68 (-14.18%)|
|+/- SMA(200)||3.35 (-31.34%)|